901792-87-8

Basic information

• Product Name: 4-((6-hydroxyhexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide
• Synonyms: 4-((6-hydroxyhexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide
• CAS NO: 901792-87-8
• Molecular Weight: 342.373
• Mol File: 901792-87-8.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 4-((6-hydroxyhexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((6-hydroxyhexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide(901792-87-8)
• EPA Substance Registry System: 4-((6-hydroxyhexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide(901792-87-8)

Safety Data

• Hazardous Substances Data: 901792-87-8(Hazardous Substances Data)

Upstream product

• 103-04-8 (phenylthio)acetic acid 
• 629-11-8 1,6-hexanediol 
• 66074-00-8 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 

Downstream Products

• 1295578-78-7 3-(phenylsulfonyl)-4-(6-(2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoyloxy)hexyloxy)-1,2,5-oxadiazole-2-oxide 
• 1186196-67-7 C₁₈H₂₂N₂O₉S 
• 1309235-48-0 C₂₉H₃₅N₃O₁₀S 
• 1309235-34-4 C₃₈H₄₅N₃O₁₂S 
• 1309235-50-4 C₃₆H₄₁N₃O₁₁S 
• 1309235-52-6 C₄₀H₄₃N₃O₁₀S 
• 1436851-41-0 C₄₀H₄₃ClN₈O₁₀S 
• 1538580-58-3 (Z)-4-((6-(2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetoxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole2-oxide 
• 1538580-67-4 (Z)-4-((6-(2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetoxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 
• 1538580-49-2 (Z)-4-((6-(2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetoxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 

Relevant articles and documents

Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity

Based on the multi-mechanism antitumor strategy and the regulatory effect of nitric oxide (NO) on histone deacetylases (HDACs), a series of N-acyl-o-phenylenediamine-based HDAC inhibitors equipped with the phenylsulfonylfuroxan module as NO donor was desi

Aurovertin B derivative as well as preparation method and application thereof

The invention provides an aurovertin B derivative, a preparation method of the aurovertin B derivative, and an application of the aurovertin B derivative in the preparation of a medicine for treatingtriple negative breast cancer. The polarity of the aurov

Design, synthesis and apoptosis-related antiproliferative activities of chelidonine derivatives

To get chelidonine derivatives with enhanced antiproliferative activity and selectivity, a series of nitric oxide donating derivatives (10a-f and 11a-j) were designed, synthesized and biologically evaluated. Compared with chelidonine, these compounds exhibited lower IC50 values against human hepatoma cells HepG2, breast cancer cells MCF-7, colon cancer cells HCT-116, as well as leukemia cells K562. Compound 11j displayed the strongest antiproliferative activity with IC50 values of 3.91, 6.90, 4.36 and 1.12 μM against the above four cells, respectively. Nevertheless, it showed an IC50 value >40 μM against human peripheral blood mononuclear cells (PBMCs), which demonstrated high selectivity between normal and cancer blood cells. In further mechanism studies, 11j showed the capability to induce K562 cells apoptosis, S phase cell cycle arrest and mitochondrial membrane potential disorder. Besides, 11j was found to be effective in promoting the expression of proapoptotic protein Bad and suppressing the expression of anti-apoptotic proteins Bcl-xL, catalase, survivin, claspin and clusterin.